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Abstract 
Aims: The inability of kidneys to prevent urinary protein leakage represents the earliest sign 
of renal damage in diabetic kidney disease (DKD). Recent data suggest the possible 
nephroprotective role of the dipeptidyl peptidase-4 (DPP-4) inhibitors. We aimed to 
investigate whether serum DPP-4 activity is associated with urine albumin excretion (UAE) in 
patients with type 1 diabetes (type 1 DM). 
Methods: DPP-4 activity and UAE measurement were performed in 113 patients with type 1 
DM and glomerular filtration rate (GFR) within normal range. They were divided into three 
groups according to UAE tertiles. 
Results: Worse lipid profile and higher waist circumference were observed in the group with 
highest DPP-4 activity. Patients within lowest UAE tertile group had lowest DPP-4 activity 
value (p<0.001) compared to group within second and third tertile of  UAE.  DPP-4 activity 
correlated with systolic blood pressure (ρ=0.142; p=0.001), HbA1c (ρ=0.133; p=0.013) and 
UAE (ρ=0.349; p<0.001). In the linear regression analysis when DPP-4 activity was adjusted 
for age, gender,  disease duration, HbA1c, waist circumference, the use of ACEI and 
hypolipemic agents the association remained significant; UAE increased for 8.136 mg/24h by 
each increase of DPP-4 activity of 1 U/L (p<0.008)  
Conclusion: Our results indicate that serum DPP-4 activity is associated with albuminuria in 
type 1 diabetes. This arises the question whether the use of DPP-4 inhibitors might serve as an 
additional therapeutic strategy to prevent proteinuria in patients with DKD. 
Key words: albuminuria, dipepidyl peptidase-4, type 1 diabetes mellitus, diabetic kidney 
disease 
 
1. Introduction 
Diabetic kidney disease (DKD) represents one of the most frequent microvascular 
complications of diabetes mellitus (DM) with an increasing prevalence worldwide [1]. It is 
defined by the presence of albuminuria followed by decreased glomerular filtration rate 
(GFR) [2]. The inability of kidneys to prevent urinary protein leakage represents an important 
early sign of renal damage in patients with diabetes [3] which is accompanied by several 
histological abnormalities. Characteristic glomerular changes in DKD include podocyte loss, 
glomerular basement membrane (GBM) thickening and mesangial expansion due to increased 
mesangial matrix and hypertrophy of mesangial cells [4]. Over time, due to mesangiolysis 
there is a disruption and disintegration of the normal glomerular architecture which leads to 
microaneurysm formation, decrease in filtration surface area and gradual GFR reduction. 
Numerous studies have shown that the risk of DKD is tightly linked to poor glucose control 
accompanied with dyslipidemia and hypertension in both type 1 and type 2 diabetes mellitus 
(DM) [5-8].  
Dipeptidyl peptidase-4 (DPP-4) is a serine exopeptidase distributed throughout the body that 
cleaves numerous substrates such as glucagon-like peptide 1 (GLP-1) and glucose-dependent 
insulinotropic polypeptide (GIP) which play an important role in glucoregulation by 
stimulating insulin release in a glucose-dependent manner [9]. Thus, DPP-4 inhibitors 
represent a relatively novel class of oral glucose-lowering agents with good efficacy in 
treatment of type 2 DM.  The kidney is where DPP-4 is expressed at the highest level per 
organ weight [10, 11] and the clinical observations suggest that they might decrease 
albuminuria in patients with type 2 DM [12]. 
Recent data, however, suggest that DPP-4  activity is higher in patients with T1DM compared 
to healthy controls independently of islet-cell antibody status, C-peptide concentration, 
disease duration or glycated hemoglobin (HbA1c) even when compared to type 2 DM [13, 
14]. So far, there are interesting findings emerged from experimental studies which 
demonstrated the protective effect of DPP-4 inhibitors on the DKD in insulin deficient 
diabetic mice [15, 16].  
Since patients with DKD have a markedly increased risk of cardiovascular complications [5, 
6] the identification of novel DKD biomarkers that might contribute to better understanding of 
the disease or even provide a pathway to potential novel therapeutic approaches is of a special 
clinical interest. Thus, we aimed to investigate whether serum DPP-4 activity is associated 
with albuminuria in patients with type 1 DM. 
 
 
2. Methods 
The study was performed at the In-Patient Department of Diabetology of the Vuk Vrhovac 
University Hospital, Medical School University of Zagreb, Croatia and included 113 type 1 
DM patients. Histories, complete physical examination and laboratory tests were performed in 
all subjects in order to exclude diseases other than T1DM or medications that might affect 
cause transient increases in urine albumin excretion (UAE) rate such as fever, marked 
exercise or exacerbations of congestive heart failure, or resistant hypertension [17]. 
Type 1 DM was defined by undetectable meal stimulated C-peptide concentrations (C-peptide 
<0.2 ng/mL) and positive islet cell and glutamic acid autoantibodies (at least from the 
previous medical record if the measurement was performed in our Clinic laboratory, 
respectively). All of the patients were non-smokers and were not using any glucose lowering 
agent except insulin which was administered by a basal-bolus regimen. Furthermore, patients 
with glomerular filtration rate <90 ml/min/1.73m2 were not included. In total, 125 patients 
were approached; two refused to participate, 6 had concomitant respiratory infection and 4 
had urinary tract infection. The study was conducted according to the guidelines laid down in 
the Declaration of Helsinki and approved by local Ethics committee. Written informed 
consent was obtained from and signed by all patients. 
Fasting venous blood samples were collected for the determination of a complete blood count 
(CBC), glycated haemoglobin (HbA1c, %, reference interval 3.5–5.7), C-reactive protein 
(CRP), serum creatinine and liver function tests in order to exclude a wide range of disorders 
that might affect the study results. 
UAE was measured from at least two 24-h urine samples and determined as the mean of 24-h 
urine from two consecutive days to minimize variability. Serum creatinine was measured in 
fasting blood sample. Data on serum creatinine levels, age, sex and race were used to 
calculate the estimated glomerular filtration rate (eGFR) using the Chronic Kidney Disease 
Epidemiology Collaboration (CKD-EPI) formula, which was shown to be accurate in 
determining renal function in diabetic patients with normal renal function [18, 19] . 
Blood pressure was measured in the sitting position with a mercury sphygmomanometer with 
a cuff appropriate to the length and circumference of the arm after a resting period of 10 
minutes and expressed in mmHg. Patients taking blood pressure medications or with blood 
pressure >140/90 mmHg were considered to have hypertension. Fasting venous blood 
samples were collected for the determination of biochemistry panel, lipid profile status, 
HbA1c. Cholesterol and triglycerides in serum were measured by an enzymatic colorimetric 
method. Beside the lipid profile status, those patients with history of lipid-lowering agents 
consumption were considered to have dyslipidaemia.  HbA1c was measured 
spectrophotometrically by turbidimetric immuno-inhibition (Olympus AU600, Beckman-
Coulter, USA). 
DPP-4 activity was measured by a colorimetric assay procured from Sigma, St. Louis, MO, 
USA in a microplate reader (Cary Eclipse Varian, Agilent Technologies) at 460 nm, 37 °C in a 
continuous monitoring for 35 min. In this assay, DPP-4 cleaves H-Gly-Pro-AMC to release a 
ﬂuorescent product, 7-Amino-4-Methyl Coumarin (AMC) which can be measured 
spectrophotometrically as previously described [20]. One unit of activity was deﬁned as the 
amount of enzyme which will hydrolise the DPP-4 substrate to yield 1.0 μmol of AMC per 
minute at 37 °C.  
 
The data distribution was assessed by Shapiro-Wilk test. All the continuous variables are 
reported as median and range, whereas categorical variables were reported as numbers and 
percentages. The differences between study groups were tested by χ2 test for the attributive 
variables. Correlations between parameters were determined using parametric Spearmans 
correlation coefficient. All the tests were two-sided. The association between DPP-4 activity 
and UAE was further evaluated in multivariate linear regression. Adjustments were performed 
for gender, age, disease duration, HbA1c value, hypertension, ACEI use, dyslipidaemia (i.e. 
the use of statins). Statistical interference is based on 95% confidence intervals (CIs) and 5% 
P values. All statistical analysis was conducted using the statistical package Statistical 
Package for the Social Sciences (SPSS) ver.17.0 for Windows.  
 
 
 
3. Results 
 
The median age of our  study population was 51 (21-74) years with a duration of diabetes 19 
(10.5-28) years. Seventy five (66.37%) were male. Patients were divided into three groups 
according to the tertiles of albuminuria. Eighty-one (71.68%) participants were using 
angiotensin-converting enzyme (ACE) inhibitors while 50 (44.24%) had diagnosed 
hypertension. There was no significant difference in the ACEI use (N=30 vs 25 vs 26, 
p=0.064), however, nor there was difference in hypertension presence inbetween groups of 
UAE (N=19 vs 17 vs 22, p=0.803). Furthermore, when patients were divided into two groups 
according to the ACE use in order to evaluate the potential effect of ACEI on DPP-4 activity, 
no significant difference was observed (28.82 (21.53-39.53) vs 31.92 (21.48-39.92), p=0.779). 
Fourty nine (43.44%) were using statins with a higher rate in the group with higher UAE (N= 
13 vs 16 vs 20, p=0.006). The detailed clinical and laboratory findings and the difference 
between them are given in Table 1.. The group of patients with higher UAE showed higher 
DPP-4 activity (<0.001) compared to the group with lower UAE without difference in the 
GFR, however, they also did have a higher frequency of both non-proliferative and 
proliferative retinopathy (p=0.002).  DPP-4 activity showed positive correlation with systolic 
blood pressure (ρ=0.142; p=0.001), HbA1c (ρ=0.133; p=0.013) and UAE (ρ=0.349; p<0.001). 
The simple linear regression with UAE as dependent variable has shown that it increases by 
9.764 mg/24 h by each increase of DPP-4 activity of 1 U/L (p<0.006). Furthermore, when 
DPP-4 activity was additionally adjusted for the possible confounders in five different models 
(Table 2.), the association remained significant, showing that  UAE increases for 8.583 
mg/24h by each increase of DPP-4 activity of 1 U/L (p<0.008) controlled for age, gender,  
disease duration, HbA1c, BMI, hypertension presence, the use of ACEI and hypolipemic 
agents (Table 2.).  In addition, using a separate linear regression model, we found that by each 
increase of DPP-4 activity of 1 U/L systolic blood pressure increases for 1.054 (1.006-1.611, 
p=0.004), while the association with diastolic blood pressure (0.119 (-0.045-0.283), p=0.153) 
and HbA1c (0.012 (-0.012-0.026), p=0.325) was not significant. Finally, in the binary linear 
regression, DPP-4 wassignificantly associated with diabetic retinopathy presence (1.377 
(1.145-1.655), p<0.001). 
 
4. Discussion 
 
This cross-sectional study was designed in order to examine the association of serum DPP-4 
activity with UAE in a population of patients with type 1 DM with GFR within the normal 
range. It revealed that UAE is higher in those individuals with higher serum DPP-4. 
Additionally, beyond already well-established factors associated with albumiuria (HbA1c, 
obesity and hypertension), we showed that serum DPP-4 activity is significantly higher in 
type 1 DM patients with albuminuria and that the association remained significant in the 
linear regression analysis after adjustments for the well established confounders. This finding 
is partially in support to recent meta-analysis derived from clinical observations which 
suggest that the use of DPP-4 inhibitors for type 2 DM treatment has pleiotropic effects 
besides glycaemic control, i.e. that it might be effective in albuminuria reduction [12]. 
However, none of the studies was primarily designed to test the effect of DPP-4 activity on 
microalbuminuria and renal function nor the correlation between DPP-4 activity and albumin 
excretion. 
The presence of albuminuria implies either glomerular filtration barrier and/or in tubular 
reabsorption dysfunction [21]. Podocyte loss is one of the first changes contributing to 
increased glomerular permeability for albumin [22]. Nevertheless, albuminuria may also 
occur in the complete absence of structural changes of podocytes [23]. Tubular dysfunction is 
another important player promoting albuminuria by lysosomal dysfunction which is promoted 
by renin-angiotensin system (RAS) activation [24]. It results in increase of circulating levels 
of renin, angiotensinogen, angiotensin-converting enzyme [ACE), aldosterone and 
angiotensin II (AngII) increase is associated with DKD. AngII is widely known to adversely 
affect the progression of renal disease by a sum of mechanismsItleads to induction of 
intrarenal inflammation and cell apoptosis which is why ACE and AngII inhibitors found their 
place in DKD prevention and treatment [25]. We did not find the difference in the use of ACE 
inhibitors (ACEI) between two study groups, neither the difference in the serum DPP-4 
activity reached statistical significance betweev ACEI users and nonusers. Moreover, in the 
regression analysis after adjustment for the ACEI use, DPP-4 activity remained positively 
associated to UAE. 
Although there are several studies linking DPP-4 activity to albumiuria and DKD [11, 15, 16] 
the exact mechanisms linking DPP-4 activity and renal injury is still largely speculated.  DPP-
4 is normally bound on the surface of many cell types including kidney proximal tubular and 
endothelial cells [10]. Recently, Kanasaki et al. (2014) [11] found that DPP-4 protein 
expression and activity levels of DPP-4 was increased in the whole kidney lysate, endothelial 
cells, tubules, and glomeruli of streptozotocin (STZ)-induced diabetic kidney while 
microvesicle-bound DPP-4 secreted from tubular epithelial cells that can be detected in urine 
may be an early marker of renal damage before the onset of albuminuria [26]. Sun et al. 
(2012) [26] described higher urinary microvesicle DPP-4 levels in patients with diabetes 
compared to nondiabetic controls that positively correlated with extent of albuminuria in 
patients. In addition, Liu et al. (2012) [27] reported that the administration of the DPP-4 
inhibitor vildagliptin for 24 weeks prevents  kidney damage in STZ-induced diabetic rats. 
Furthermore, DPP-4 inhibitor linagliptin worked very well in an animal model of type 1 
diabetic nephropathy on top of guideline based background medication [28] and it is worth of 
mention that it works even in non-diabetic CKD models [29]. 
Renal effects of DPP-4 inhibitors appear to be mediated by targeting diabetes related 
abnormalities: hyperglycaemia, dyslipidaemia along with oxidative stress and low grade 
inflammation in a direct or indirect pathway. Hyperglycaemia is recognized as the most 
important factor for DKD development and progression in type 1 DM [7]. Increased systemic 
DPP-4 activity degradates incretine hormones GLP-1 and GIP and thus might contribute to 
glycaemic control deterioration and the increase in advanced end glycosilation production and 
thus causes renal injury [30]. Dyslipidaemia, defined as high total cholesterol, high low-
density lipoprotein cholesterol and low high-density cholesterol with race cut-off’s  may 
cause renal mesangial and epithelial cell injury and promote renal disease progression [31, 
32]. Recently, Tanaka et al. (2016) [15] provided the evidence on the possible renoprotective 
effect of DPP-4 inhibitors in cultured mouse proximal tubular cells by inhibiting 
tubulointerstitial injury induced by inflammation, fibrosis, and apoptosis in mice without 
altering systemic characteristics including body weight, fasting blood glucose, and food 
intake. The increased serum DPP-4 activity might increase the degradation process of 
endogenous GLP-1 resulting in worsening of the mentioned parameters. According to current 
literature, DPP‑ 4 inhibition and the GLP‑ 1 receptor each play an important role in this 
process that appears to be independent of any associated impact on blood glucose which is 
also in support with our study results since we did not found a significant association between 
DPP-4 activity and HbA1c in the linear regression model. The relevance of the GLP‑ 1 
receptor is supported due to its expression on podocytes. In line with this, there are data 
showing that kidney protection in diabetic animals can be achieved with the GLP‑ 1 
analogues, as well. The pathway comprising DPP‑ 4, GLP‑ 1 and the GLP‑ 1 receptor 
presents several an interesting features in the setting of DKD [33]. Furtermore, an observation 
that DPP‑ 4 activity inhibition decreases NHE3 exchanger function, a transporter that 
mediates sodium reabsorption in renal proximal tubule could provide an additional connection 
between glucose homeostasis, renal function and blood pressure that links DPP-4 activity with 
DKD.  
In our study, we found that DPP-4 activity is associated with systolic blood pressure that as 
already mentioned might cause podocyte loss [23-25]. It is proposed that DPP-4 inhibition 
reduces microvascular tone through direct nitric oxide (NO) system preventing acute 
podocyte ischemia events.  Therefore, we can generate the conclusion that increased serum 
DPP-4 activity might increase vascular tonus resulting in podocyte and/or tubular lesions that 
gradually lead to albumin leakage, endothelial proliferation, nodule formation, decrease in 
filtration surface area and gradual GFR reduction that is similar patophysiological process to 
diabetic retinopathy developmet, and we did found a significant association between 
retinopathy presence and DPP-4 activity as previously described [34] .Our  results indicate 
only that serum DPP-4 activity is strongly associated with albuminuria in type 1 DM patients 
and thus that it might be of a great importance in DKD development in addition to already 
known risk factors. However, the lack of control group and the cross-sectional study design 
clearly diminishes its power for deriving any general conclusions. In addition, we did not 
measure urinary DPP4 activity which would be much closer to the local kidney DPP4 activity 
as compared to serum DPP4 activity and provided us with more relevant results. However, we 
do believe that even this results raise the question whether the use of DPP-4 inhibitors might 
serve as an additional therapeutic strategy to protect proximal tubular cells against proteinuria 
in patients with DKD. Thus, the relationship between DPP-4-activity and DKD progression in 
the prospective analysis would be of great interest. 
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Table 1. Patients anthropometric and laboratory characteristics according to the DPP-4 
activity median value 
 
Variable Urine albumin 
excretion  
<23.55 mg/24h 
N=37 
Urine albumin 
excretion  
>23.55-41.08 
mg/24h 
N=40 
Urine albumin 
excretion  
>41.08-365.6 
mg/24h 
N=36 
p 
Age (years) 50 (21-74) 51 (23-71) 53 (27-65) 0.812 
Gender (M/F) 23/14 25/15 22/14 0.056 
BMI (kg/m2) 25 (20-29) 23 (19-30) 26.5 (23-33) 0.067 
Waist circumference (cm) 87.5 (81-97.5) 91 (68-102) 91 (72-111) 0.019 
Diabetes duration (years) 24 (21-46) 26 (25-34) 24 (22-36) 0.563 
HbA1c (%) 7.1 (5.2-9.3) 7.2 (5.5-11.7) 7.0 (6.2-8.1) 0.886 
Heart rate (beats  per minute) 72 (46-104) 75 (53-100) 71 (50-106) 0.067 
Systolic blood pressure (mmHg) 125 (100-145) 120 (110-160) 120 (100-155) 0.975 
Diastolic blood pressure (mmHg) 80 (65-100) 80 (70-100) 80 (75-90) 0.553 
Total serum cholesterol (mmol/L) 4.98 (3.22-6.70) 5.31 (4.49-6.48) 4.73 (3.77-5.61) 0.573 
HDL cholesterol (mmol/L) 1.56 (1.03-2.89) 1.74 (1.22-2.25) 1.51 (1.03-1.72) 0.347 
LDL cholesterol (mmol/L) 2.81 (0.99-3.95) 2.70 (1.60-3.75) 2.87 (1.92-3.39) 0.452 
Triglycerides (mmol/L) 1.11 (0.52-2.72) 1.02 (0.87-2.58) 1.10 (0.71-1.53) 0.214 
Serum creatinine (µmol/L) 72 (49-84) 57 (41-90) 78 (64-90) 0.058 
CKD-EPI (mL/min/1.73 m
2
) 98 (90-130) 108 (94-110) 98 (28-90) 0.558 
Urine albumin excretion 
(mg/24h) 
5.4 (1.55-23.55) 31.80 (23.55-41.08) 174.80 (41.10-365.6) <0.001 
Non-proliferative retinopathy 
presence  (N, %) 
6 (16.21) 11 (27.5) 18 (50.0) 0.002 
Proliferative retinopathy presence 
(N, %) 
0 (0) 1 (2.5) 8 (22.2) <0.001 
C reactive protein (mg/L) 1.1 (0.1-4.9) 2.6 (0.1-3.6) 4.8 (0.1-4.9) 0.347 
AST (U/L) 22 (10-44) 24 (17-34) 24 (17-34) 0.602 
ALT (U/L) 21 (13-58) 26 (10-31) 20 (17-35) 0.860 
GGT (U/L) 19 (9-63) 23 (18-56) 24 (11-42) 0.278 
AP (U/L) 77 (61-115) 87 (75-99) 78 (66-109) 0.479 
DPP-4 activity (U/L) 24.55 (19.21-36.20) 30.86 (22.41-38.31) 37.79 (27.86-39.53) <0.001 
 
Legend: DPP-4: dipeptidyl peptidase; AST: aspartat aminotransferase; ALT: alanin aminotransfrerase; GGT: 
gamma glutamil transferase; AP:alkaline phosphatase; CKD-EPI: Chronic Kidney Disease Epidemiology 
Collaboration formula 
 
 
Table 2. Linear regression analysis for the serum DPP4 activity (U/L) and the UAE (mg/24h) 
derived from twoseparate models 
 
    95% confidence interval 
 B β p Lower bound Upper bound 
MODEL 1  
 
9.764 
 
 
0.270 
 
 
0.006 
 
 
2.821 
 
 
       16.707 
 
Serum DPP 
activity (U/L) 
MODEL 2      
Serum DPP 
activity (U/L) 
8.136 0.309 0.009 2.112 14.160 
Age (years) 
Gender (male) 
1.606 0.067 0.549 -3.696 6.908 
3.617 0.142 0.241 -5.251 7.485 
Disease 
duration (years) 
2.743 0.110 0.305 -2.546 8.031 
HbA1c (%) 14.254 0.066 0.518 -57.933 29.424 
ACEI use (%) -1.161 -0.002 0.985 -127.499 125.177 
Systolic blood 
pressure 
(mmHg) 
1.182 0.071 0.514 -4.769 2.404 
Waist 
circumference 
(cm) 
2.172 0.090 0.483 -3.962 8.306 
 
 
 
 
 
 
 
